Neurocrine Biosciences, Inc. (NBIX) Profit Margins
Over the twelve months to 2026-06-30, Neurocrine Biosciences, Inc. (NBIX) had operating margin 23.6%, net margin 20.9%, free cash flow margin 25.8%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NBIXNeurocrine Biosciences, Inc.Follow NBIX — free
—
Price chart with a free account
- Market cap
- 14.5B
- P/E TTM
- 20.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | 99.2% | 98.9% | — | 99.0% | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% | — | |
| Operating margin | 43.8% | 2.7% | -1701.9% | -476.5% | -982.5% | -81.3% | 8.2% | 9.2% | 15.6% | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% | 23.6% | |
| Net margin | 48.5% | 9.5% | -1579.0% | -449.8% | -940.6% | -88.2% | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% | 20.9% | |
| FCF margin | -1.9% | -68.2% | -1033.0% | -202.0% | -735.3% | -62.7% | 17.0% | 16.8% | 20.8% | 20.6% | 21.7% | 19.2% | 23.7% | 26.2% | 25.8% |
USD billions · SEC XBRL
Neurocrine Biosciences, Inc. — questions
- What is Neurocrine Biosciences, Inc.'s operating margin?
- 23.6% over the twelve months to 2026-06-30.
- What is Neurocrine Biosciences, Inc.'s net profit margin?
- 20.9% over the twelve months to 2026-06-30.
Every figure on this page comes from Neurocrine Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.